Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Surface Oncology, Inc. (SURF)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.0500-0.1100 (-9.48%)
At close: 04:00PM EDT
1.1000 +0.05 (+4.76%)
After hours: 04:03PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • T
    The Trades
    This is the forgotten gem
  • C
    Chari
    Cash is more than twice the market cap.
  • T
    The Trades
    New medications
  • P
    P
    Keep shorting it easy money
    Bearish
  • P
    P
    Keep shorting lots to fall still
    Bearish
  • P
    P
    Congrats on the new 52 week low keep shorting
    Bearish
  • g
    gene_genome
    --HC Wainwright Adjusts Price Target on Surface Oncology to $8.50 From $10, Reiterates Buy Rating..
  • P
    P
    Short any move up always gives it right back
    Bearish
  • א
    איתן
    What do you guys think of the report from this quarter?
    Enlighten people who are not well-versed in the field...
  • B
    BIO_INVEST
    SURF 16:38 05/17/21
    Surface Oncology initiated with a Buy at BTIG BTIG analyst Justin Zelin initiated coverage of Surface Oncology with a Buy rating and $17 price target. The early-stage company is developing multiple antibodies to treat a variety of solid tumor cancers with novel mechanisms of action, Zelin said. SRF617 is its lead asset targeting patients with solid tumors in gastric, pancreatic and prostate cancer, Zelin noted.
  • P
    P
    Nice hope the pop holds makes it easy short if it does
    Bearish
  • R
    RV
    Milestones announced @ Q2/2021:

    Investigational New Drug (IND) filing for GSK4381562 formerly, SRF813, targeting the PVRIG checkpoint and partnered with GlaxoSmithKline, anticipated in 2H 2021.

    Data update from Phase 1 study of SRF617 anticipated in late 2021.

    Data update from Phase 1 study of SRF388 anticipated in early 2022.
  • M
    Martin
    ark bought 2,8M more, yesterday, not much but still, they are increasing position means the potential is higher
    Bullish
  • M
    Moral empirical
    Jeez...it’s the same pattern for most stocks , especially biopharma.
    They most always retrace over bought speculate gains down to .38, .5 & .62 Fibonacci.
    SURF bounced hard and fast 20 cents above .62 fib during last months NASDAQ correction.
    All MM algos are programmed using fibs and the half way points between them.
    Personally I’m really appreciative to have the opportunity to invest with SURF’s proven top tier management.
    Funding operations with a optioned out molecule to GSK for $85 mn plus 750mn for mile stones thats still in pre clinical stage.
    That says something about these guys ability to develop complex molecules.
    Now with $160 in undilutive funding to 2023 with $10mn Q burn.
    2 ph1 trials progressing with SRF 388 fast tracked for liver cancer with total of 4 trials to be ongoing by Q3.
    GLTA.
  • I
    Investor Lad
    I added this company to my 5 year portfolio. This will easily 30x in 5 years.
    Bullish
  • I
    Ibott
    30,000 more shares bought today by ark. What does Cathie know?
    Bullish
  • a
    art
    Cathy wood bought 33,000 plus shares today! Her ark fund has been buying almost every week!
  • H
    Heavenly Girl
    What is the next catalyst for SURF? I bought in at $8.50 and have watched my investment dwindle. I would like to buy more, but am not sure at what price. Thanks.
  • M
    Matterhorn
    Newsletter Cathie Wood Ark says

    Today, Surface Oncology, a company developing first-in-class antibody therapies for the treatment of solid tumors, traded up more than 17% in response to analyst upgrades as well as positive AZ results involving a monoclonal antibody that targets an overexpressed gene in non-small cell lung cancer known as CD73. Surface Oncology has licensed its CD73 technology to NVS.
  • e
    ebby
    For a company with market cap 366m, got a 800m deal from GSK, upfront pay 85m, plus future loyalty, which is a fantastic news !!! There is no way sp should go down. I am confident with my shares. It's going to close green today. People need time to see and digest the news. no worries here !
    Bullish
Advertisement
Advertisement